echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > ARD: Behçet's disease risk variant HLA-B51/ERAP1-Hap10 alters human CD8 T-cell immunity

    ARD: Behçet's disease risk variant HLA-B51/ERAP1-Hap10 alters human CD8 T-cell immunity

    • Last Update: 2022-09-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    OBJECTIVE: The endoplasmic reticulum (ERAP1) haplotype Hap10 encodes an endoplasmic reticulum (ER) resident peptide trimming allotype of the aminopeptidase ERAP1 with low enzymatic activity


    Methods: We genotyped and immunophenotyped 26 untreated Turkish BD subjects and 22 healthy donors to generate CRISPR-Cas9 ERAP1 knockout cells (KO ), analyzed peptide length differences of HLA class I-binding peptide sets and assessed the immunogenicity of genome-edited cells in a CD8 T cell co-culture system


    RESULTS: The allele frequencies of ERAP1-Hap10 were similar to previous studies


    Conclusions: This study demonstrates that low activity ERAP1 alters immunogenicity to CD8 T cells, mediated by an HLA class I peptide set with under-trimmed peptides


    Credit: Cavers A, Kugler MC, Ozguler Y, Al-Obeidi AF, Hatemi G, Ueberheide BM, Ucar D, Manches O, Nowatzky J.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.